We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Global Blood Therapeutics Inc | NASDAQ:GBT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 68.49 | 68.47 | 68.50 | 0 | 00:00:00 |
From Jan 2022 to Jan 2025
By Colin Kellaher
Shares of Global Blood Therapeutics Inc. edged higher in premarket trading Monday after the biopharmaceutical company agreed to be acquired by Pfizer Inc. in a transaction valued at about $5.4 billion, including assumed debt.
New York-based Pfizer said it would pay $68.50 a share in cash for Global Blood, a 7.3% premium to Friday's closing price of $63.84 but more than double its closing price of $33.93 on Aug. 3, before published reports emerged that potential buyers were circling the South San Francisco, Calif., company.
Global Blood shares, which ended Friday's session with a gain of 33%, were recently changing hands at $66.36, up 4%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 08, 2022 07:14 ET (11:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Global Blood Therapeutics Chart |
1 Month Global Blood Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
